NICE recommends Bayer’s EYLEA® as first-line treatment option

pharmafield logo - pharma news

The National Institute for Health and Care Excellence (NICE) has recommended Bayer’s EYLEA® (aflibercept) as a cost-effective first-line treatment option for adults with visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO) within a draft Final Appraisal Determination (FAD).

In the draft guidance, NICE concluded that aflibercept is more clinically effective than the existing first-line treatment – laser photocoagulation – for untreated visual impairment caused by macular oedema after BRVO. NICE also concluded that aflibercept is more clinically effective when given before, rather than after, laser photocoagulation.

The decision means that over 13,000 patients will have first-line access to a treatment that has been proven to achieve superior improvements in vision compared to the existing first-line treatment.

If not treated effectively, macular oedema secondary to BRVO can significantly impact a person’s vision.

All patients, including those newly diagnosed, will now have access to treatment which reflects the Royal College of Ophthalmologists treatment guidelines. 

Professor Sobha Sivaprasad, Consultant Ophthalmologist, Moorfields Eye Hospital, London, said: “This is great news for the clinical community as it means we will be able to offer patients with BRVO the same opportunity to achieve improvements in vision, as those with other retinal conditions. This recommendation will also mean that treatment decisions could be simplified, with fewer interventions and NHS resources required to ensure patients are achieving the best possible visual outcomes.”  

Dr Alexander Moscho, CEO, Bayer UK/Ireland commented: “We are delighted that NICE has recognised the value of EYLEA® and the benefits that it can bring to patients and the clinical community. At Bayer we are committed to ensuring all eligible patients have access to EYLEA® in line with the market authorisation so it is great news for patients with BRVO who will have access to this effective treatment as soon as possible in the treatment pathway.”